Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

SWOG study shows significant long-term overall survival for advanced gastrointestinal stromal tumor patients with imatinib treatment.

Trautmann M, Huss S, Hartmann W, Wardelmann E.

Transl Gastroenterol Hepatol. 2018 Feb 8;3:10. doi: 10.21037/tgh.2018.01.09. eCollection 2018. No abstract available.

2.

S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.

Blanke CD, Rankin C, Corless C, Eary JF, Mulder K, Okuno SH, George S, Heinrich M.

Oncologist. 2015 Dec;20(12):1353-4. doi: 10.1634/theoncologist.2015-0295. Epub 2015 Nov 17.

3.

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA.

J Clin Oncol. 2008 Nov 20;26(33):5360-7. doi: 10.1200/JCO.2008.17.4284. Epub 2008 Oct 27.

4.

What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?

Rutkowski P, Andrzejuk J, Bylina E, Osuch C, Switaj T, Jerzak vel Dobosz A, Grzesiakowska U, Jurkowska M, Woźniak A, Limon J, Dębiec-Rychter M, Siedlecki JA.

Med Oncol. 2013 Dec;30(4):765. doi: 10.1007/s12032-013-0765-7. Epub 2013 Nov 12.

5.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H.

J Clin Oncol. 2008 Feb 1;26(4):620-5. doi: 10.1200/JCO.2007.13.4403.

PMID:
18235121
6.

Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.

Le Cesne A, Blay JY, Reichardt P, Joensuu H.

Oncologist. 2013;18(11):1192-9. doi: 10.1634/theoncologist.2012-0361. Epub 2013 Oct 17. Review.

7.

Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.

Lin JX, Chen QF, Zheng CH, Li P, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Huang CM.

J Cancer Res Clin Oncol. 2017 Apr;143(4):727-734. doi: 10.1007/s00432-016-2334-x. Epub 2017 Jan 12.

PMID:
28083710
8.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL.

Ann Surg Oncol. 2012 Apr;19(4):1074-80. doi: 10.1245/s10434-011-2190-5. Epub 2011 Dec 28. Erratum in: Ann Surg Oncol. 2012 Jul;19(7):2420.

9.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H.

N Engl J Med. 2002 Aug 15;347(7):472-80.

10.

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.

Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schöffski P, Leyvraz S, Italiano A, Grünwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litière S, Marreaud S, van der Graaf W, Gronchi A, Verweij J; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group.

J Clin Oncol. 2017 May 20;35(15):1713-1720. doi: 10.1200/JCO.2016.71.0228. Epub 2017 Mar 31.

PMID:
28362562
11.

Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.

Saito S, Nakata K, Kajiura S, Ando T, Hosokawa A, Sugiyama T.

Digestion. 2013;87(1):47-52. doi: 10.1159/000343938. Epub 2013 Jan 21.

12.

Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study.

Hsu JT, Le PH, Kuo CF, Chiou MJ, Kuo CJ, Chen TH, Lin CJ, Chen JS, Yu HP, Yeh CN, Jan YY, Yeh TS.

Oncotarget. 2017 Apr 3;8(41):71128-71137. doi: 10.18632/oncotarget.16795. eCollection 2017 Sep 19.

13.

Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.

Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW.

Ann Surg Oncol. 2007 Jan;14(1):14-24.

PMID:
17072676
14.

Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.

Wu L, Zhang Z, Yao H, Liu K, Wen Y, Xiong L.

Drug Des Devel Ther. 2014 Oct 30;8:2061-7. doi: 10.2147/DDDT.S63840. eCollection 2014.

15.

Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.

Tielen R, Verhoef C, van Coevorden F, Gelderblom H, Sleijfer S, Hartgrink HH, Bonenkamp JJ, van der Graaf WT, de Wilt JH.

Eur J Surg Oncol. 2013 Feb;39(2):150-5. doi: 10.1016/j.ejso.2012.09.004. Epub 2012 Oct 16.

16.

Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib.

Chang SC, Liao CH, Wang SY, Tsai CY, Chiang KC, Cheng CT, Yeh TS, Chen YY, Ma MC, Liu CT, Yeh CN.

Medicine (Baltimore). 2015 Jun;94(24):e1014. doi: 10.1097/MD.0000000000001014.

17.
18.

Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.

Matsumoto K, Sawaki A, Mizuno N, Hara K, Hijioka S, Niwa Y, Tajika M, Kawai H, Kondo S, Yamao K.

Jpn J Clin Oncol. 2011 Jan;41(1):57-62. doi: 10.1093/jjco/hyq164. Epub 2010 Sep 20.

PMID:
20858619
19.

Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients.

Li J, Gong JF, Li J, Gao J, Sun NP, Shen L.

World J Gastroenterol. 2012 Feb 21;18(7):698-703. doi: 10.3748/wjg.v18.i7.698.

20.

Long-term efficacy of imatinib for treatment of metastatic GIST.

Patel S.

Cancer Chemother Pharmacol. 2013 Aug;72(2):277-86. doi: 10.1007/s00280-013-2135-8. Epub 2013 Mar 17. Review.

PMID:
23503753

Supplemental Content

Support Center